combined treatment with buserelin+cabergoline in patient with prostate cancer and pituitary macroprolactinoma结合治疗buserelin +卡麦角林在前列腺癌患者和垂体macroprolactinoma.pdfVIP

Journal of Cancer Therapy, 2010, 1, 214-218 doi:10.4236/jct.2010.14033 Published Online December 2010 (/journal/jct) Combined Treatment with Buserelin+Cabergoline in Patient with Prostate Cancer and Pituitary Macroprolactinoma 1 2 3 3 3 Mihály Gervain , Erika Vörös , Andor H. Molnár , Gyöngyi Karcsú-Kis , Ferenc László Ferenc A. László3 1Department of Urology, City Hospital, Orosháza, Hungary; 2 Euromedic Diagnostics, Szeged, Hungary; 3 Department of Physiology, Anatomy and Neurosciences, University of Szeged, Szeged, Hungary. Email: laszlo.a.ferenc@freemail.hu th st th Received June 28 , 2010; revised August 1 , 2010; accepted September 5 , 2010. ABSTRACT Twelve years following hemicolectomy for colon adenocarcinoma, a 75-year-old patient with prostate cancer was treated for 4 weeks with the antiandrogen nilutamide and then with the long-acting GnRH agonist buserelin. The serum testosterone and prostate-specific antigen levels had decreased dramatically after 3 months of treatment. After 2 years of buserelin administration, the hormonal state was examined. Serum estradiol, testosterone, DHEA, DHEAS, FSH and LH levels proved to be suppressed, but the serum PRL concentration was extremely high (3 365 mIU/l). The pituitary MRI revealed a macroadenoma. The patient was treated with the dopamine agonist cabergoline, together with buserelin. After 9 months of this combined treatment, the prostate-specific antigen and testosterone levels were very low; the serum estradiol, DHEA, DHEAS, FSH and LH concentrations remained suppressed. The serum PRL level fell dramatically to 6.95 mIU/l, and a significant reduction in tumor size was observed on MRI.